MAIA Biotechnology (MAIA) awards director 27,907 options at $1.40

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. director Steven M. Chaouki received a grant of stock options for 27,907 shares of common stock on March 31, 2026. The options carry an exercise price of $1.40 per share, vest 100% on the grant date, and are exercisable immediately through March 31, 2036.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider CHAOUKI STEVEN M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	27,907	$0.00	--

Holdings After Transaction: Stock Options — 27,907 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 27,907 options Exercise price: $1.40 per share Expiration date: March 31, 2036 +3 more

6 metrics

Options granted 27,907 options Stock options for common stock granted March 31, 2026

Exercise price $1.40 per share Exercise price of granted stock options

Expiration date March 31, 2036 Option term end date

Vesting 100% on grant date Options vest fully on March 31, 2026

Shares underlying options 27,907 shares Underlying MAIA common stock per option grant

Post-grant derivative holdings 27,907 options Total options held following transaction

Key Terms

Stock Options, 2021 Equity Incentive Plan, vest 100% on the date of the grant, exercise price

4 terms

Stock Options financial

"The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

2021 Equity Incentive Plan financial

"granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan"

vest 100% on the date of the grant financial

"representing the right to buy shares of common stock, vest 100% on the date of the grant"

exercise price financial

"conversion or exercise price of $1.4000 per share for the stock options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CHAOUKI STEVEN M

(Last) (First) (Middle)

444 WEST LAKE STREET, SUITE 1700

(Street)

CHICAGO ILLINOIS 60606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.4	03/31/2026		A		27,907		03/31/2026(1)	03/31/2036	Common Stock	27,907	$0	27,907	D

Explanation of Responses:

1. The stock options, granted on March 31, 2026 pursuant to the MAIA Biotechnology, Inc's 2021 Equity Incentive Plan, representing the right to buy shares of common stock, vest 100% on the date of the grant and are exercisable beginning as of that date.

	/s/ Steven M. Chaouki	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MAIA (MAIA) report in this Form 4?

MAIA reported a grant of stock options to director Steven M. Chaouki. He received 27,907 options for common stock, which vest 100% immediately and are exercisable at an exercise price of $1.40 per share through March 31, 2036.

Who is the reporting person in MAIA (MAIA)’s latest Form 4 filing?

The reporting person is director Steven M. Chaouki. He reported receiving a grant of 27,907 stock options for MAIA Biotechnology, Inc. common stock, issued under the company’s 2021 Equity Incentive Plan, with immediate vesting and a $1.40 per share exercise price.

How many MAIA (MAIA) stock options were granted to the director?

Steven M. Chaouki was granted 27,907 stock options. These options represent the right to buy an equal number of MAIA Biotechnology, Inc. common shares, vest in full on the grant date, and remain exercisable until March 31, 2036 at $1.40 per share.

What is the exercise price and term of the MAIA (MAIA) director’s options?

The options have an exercise price of $1.40 per share and expire on March 31, 2036. They were granted on March 31, 2026, vest 100% on that date, and are exercisable beginning immediately thereafter, giving a ten-year exercise window.

When do the MAIA (MAIA) stock options granted to the director vest?

The stock options vest 100% on the grant date, March 31, 2026. According to the disclosure, they are exercisable beginning as of that date, allowing the director to purchase common shares at $1.40 per share through March 31, 2036.

Under which plan were the MAIA (MAIA) stock options granted?

The options were granted under MAIA Biotechnology, Inc.’s 2021 Equity Incentive Plan. They give director Steven M. Chaouki the right to buy 27,907 common shares at $1.40 per share, vest fully on March 31, 2026, and remain exercisable until March 31, 2036.